Pacira reports Q4 non-GAAP EPS 96c, consensus 83c

Reports Q4 revenue $187.3M, consensus $185.38M. “Pacira (PCRX) enters 2025 with a sharp focus on executing our 5×30 strategy to accelerate our transition into an innovative biopharmaceutical organization and therapeutic area leader in musculoskeletal pain and adjacencies,” said CEO Frank Lee. “The new year is off to a strong start, highlighted by the recent implementation of NOPAIN, which we believe will drive greater utilization of EXPAREL and iovera degrees by significantly expanding patient access in outpatient settings. We are confident in our ability to drive growth in our base business and advance a novel pipeline of potentially transformative assets, like PCRX-201.”